- For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer-driven insights, tools and connection
- Home Ground™ was developed in collaboration with people living with schizophrenia, care partners and mental health advocacy groups to help support wellbeing through shared experience
- As a leader in neuroscience, Teva is committed to supporting people living with complex mental health conditions through practical resources to help navigate the care journey
PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with community-informed and experienced-based information and support.
Developed in collaboration with people living with schizophrenia and care partners, Teva created Home Ground™ to connect the community, help people learn from others, feel less alone and address real-life needs with resources that are useful, understandable and actionable.
“Schizophrenia care doesn’t end with diagnosis and a prescription. The day-to-day realities, including isolation, can be very challenging and addressing these barriers is important for the recovery journey,” said Dan Laitman, a Home Ground™ Ambassador and community advocate living with schizophrenia. “As someone who has firsthand experience with the power of holistic care, I see Home Ground™ Schizophrenia Community as an essential resource that brings peer perspectives and practical support together in one place, giving individuals and care partners a true home for support alongside their clinical care.”
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.1 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, yet over 75% of people with psychotic disorders experience loneliness, which often contributes to severe depression, reduced cognitive function and poor physical health.2, 3, 4, 5, 6 Mitigating this persistent barrier necessitates active community outreach, fostering social connections and integrating social support into treatment plans.
“For those living with schizophrenia, it is clear that social isolation represents a fundamental and often primary impediment to achieving and maintaining successful recovery,” said Heather DeMyers, Vice President of Marketing, U.S. Innovative Medicines at Teva. “Home Ground™ Schizophrenia Community was developed to address this head-on. By offering practical community resources and easy-to-use tools, the platform aims to integrate social support into treatment plans so no one has to face these challenges alone.”
Home Ground™ Schizophrenia Community includes resources and tools across areas that commonly affect daily life, including:
- Symptom tracking and management tools: Practical worksheets and plans that help individuals track mood, sleep, stress and triggers, so they can bring clearer information to their providers for the most benefit from treatment.
- Emotional wellness: Resources that normalize what people and care partners are feeling, offering concrete coping strategies to reduce isolation through peer-informed insights, including videos that spotlight people living with schizophrenia and their care partners discussing their experience.
- Independent living: Guides and toolkits that support small steps toward independence through routines, reminders, community resource lists for housing and shared goal‑setting.
- Physical health: Simple prompts and checklists that encourage attention to sleep, activity and medical care, reinforcing whole‑person health alongside psychiatric treatment.
- In-person and virtual events: Local and national community events to connect people with schizophrenia and their care partners to their community.
“As a care partner, I’ve experienced firsthand just how isolating schizophrenia can be, and many people I’ve spoken with feel misunderstood and helpless as a result,” said Nicole Drapeau Gillen, care partner, schizophrenia advocate and Home Ground™ Ambassador. “By listening to stories from the community and providing practical tools to manage our daily lives, Home Ground™ helps dismantle stigma and empowers us to take manageable steps, stay connected and play an active role in care.”
All Home Ground™ Schizophrenia Community resources are available online at no cost to anyone seeking information or support, whether they are living with schizophrenia themselves, caring for someone who is, or working within the mental health community.
To learn more, visit www.HomeGroundSCZ.com
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
About Schizophrenia
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.1 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.1,2,7 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 3.5 million people in the U.S. are currently diagnosed with the condition.2,7 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.1 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.7 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.8, 9, 10 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.